Insights from BioCina
From process development to commercial manufacturing, learn more through our library of resources provided by our team of industry experts.
Featured Resource
About BioCina
Learn about BioCina’s superior FDA and cGMP approved manufacturing development and manufacturing services.
What Is Cytotoxic Drug Manufacturing?
Cytotoxic drug manufacturing is a specialized area of pharmaceutical production focused on the safe handling, formulation, and fill-finish of compounds that are toxic to living cells. Most cytotoxic drugs are used in oncology to treat cancer.
Cytotoxic drug manufacturing is a specialized area of pharmaceutical production focused on the safe handling, formulation, and fill-finish of compounds that are toxic to living cells. Most cytotoxic drugs are used in oncology to treat cancer. Their mechanism of action, targeting rapidly dividing cells, makes them among the most potent and hazardous substances manufactured in pharmaceutical facilities and why specialist oncology CDMO capability is essential for programs in this category. For this reason, cytotoxic drug manufacturing operates under a distinct set of containment, safety, and regulatory requirements that go significantly beyond standard GMP sterile manufacturing.
What Are Cytotoxic Drugs?
The term cytotoxic describes compounds that are toxic to cells. In pharmaceutical manufacturing, the category primarily includes:
- Chemotherapy agents used in oncology treatment, including antimetabolites, alkylating agents, anthracyclines, and vinca alkaloids
- Oncology immunomodulators and certain targeted therapies with cytotoxic mechanisms
- High-potency active pharmaceutical ingredients (HPAPIs) with occupational exposure limits at or below microgram-per-cubic-meter concentrations
These compounds are classified using occupational exposure bands (OEBs). OEB 4 and OEB 5 compounds require the most stringent containment measures. While cytotoxic drugs provide clinical benefit to patients, as cross-contaminants in a manufacturing environment they pose serious risk to operators and to other products. This dual nature is what makes cytotoxic drug manufacturing both technically demanding and operationally distinct from general sterile injectable manufacturing.
Why Cytotoxic Drug Manufacturing Requires Dedicated Facilities
Cytotoxic manufacturing and high-potency sterile manufacturing cannot safely share infrastructure with standard pharmaceutical production. The risk of product-to-product cross-contamination, environmental spread, and operator exposure requires physical separation at the facility level.
A purpose-built cytotoxic manufacturing environment includes:
- A self-contained manufacturing area, physically separated from the broader facility with its own HVAC, environmental monitoring, and quality systems
- Dedicated containment fill-finish infrastructure, designed and validated for cytotoxic and high-potency non-cytotoxic products under controlled changeover and cleaning protocols
- Validated cleaning and decontamination procedures specific to cytotoxic residue limits
- Operators trained in cytotoxic-specific handling, gowning, and emergency response protocols
- Dedicated waste handling processes compliant with cytotoxic waste disposal regulations
Manufacturing cytotoxic drugs without this dedicated infrastructure creates regulatory risk, supply chain risk, and patient safety risk that most pharmaceutical companies cannot accept. BioCina’s cytotoxic manufacturing facility is purpose-built and physically separated from its broader fill-finish platform, with its own HVAC, environmental monitoring, and quality infrastructure, and has operated continuously for over 30 years through successive regulatory inspection cycles..
The Role of RABS in Cytotoxic Fill-Finish
Regulatory Requirements for Cytotoxic Drug Manufacturing
Cytotoxic drug manufacturing is governed by the same GMP frameworks that HAZapply to all pharmaceutical manufacturing, including FDA 21 CFR Parts 210/211, EU GMP guidelines, and TGA requirements. Cytotoxic-specific obligations add further compliance layers:
- Dedicated facility or physically segregated suite requirements to prevent cross-contamination
- OEL and OEB documentation for each compound manufactured
- Operator health monitoring and occupational exposure assessment programs
- Validated cleaning procedures with cytotoxic-specific residue acceptance limits
- Cytotoxic waste classification and disposal documentation
Regulatory agencies inspecting cytotoxic manufacturing sites assess not only GMP compliance but the adequacy of containment infrastructure and operator safety systems. BioCina’s cytotoxic manufacturing operations are TGA-approved, with a continuous GMP compliance record built through successive TGA inspection cycles. This established regulatory standing provides a robust foundation for programs targeting Australian and global markets through TGA-approved supply.
What a Cytotoxic CDMO Partner Provides
Most clinical-stage oncology companies do not have in-house cytotoxic fill-finish capability. The capital investment, regulatory expertise, and specialized workforce required to build and qualify a compliant cytotoxic environment are prohibitive for all but the largest pharmaceutical organizations. An oncology manufacturing partner with dedicated infrastructure and established regulatory standing provides what most drug developers cannot build themselves. CDMO partnerships are the standard model for cytotoxic fill-finish at every stage of development.
A capable cytotoxic CDMO with high-potency manufacturing expertise will support:
- Feasibility assessment and formulation development for cytotoxic injectables
- Engineering and toxicology batch manufacture for regulatory submissions
- Phase I through Phase III clinical trial supply under GMP
- Process validation and scale-up for commercial manufacturing
- Multi-SKU lifecycle management for established oncology portfolios
- Technology transfer from in-house or third-party manufacturing sites
FAQs
What compounds are classified as cytotoxic?
Cytotoxic compounds include most traditional chemotherapy agents such as alkylating agents, antimetabolites, and anthracyclines, as well as certain targeted cancer therapies and high-potency active pharmaceutical ingredients (HPAPIs) with mechanisms resulting in cell death or inhibition of cell proliferation. Classification is based on pharmacological mechanism and occupational exposure band, not a single universal list.
What containment is required for cytotoxic drug manufacturing?
Cytotoxic manufacturing requires dedicated, physically separated facilities with validated barrier filling technology such as RABS, controlled ventilation and pressure differentials appropriate to the compound’s hazard classification, cytotoxic-specific cleaning validation, trained personnel with occupational health monitoring, and compliant cytotoxic waste disposal. Specific requirements depend on the OEB classification of the compound.
Can cytotoxic and non-cytotoxic products be manufactured at the same site?
Yes, but not in shared manufacturing areas. Regulatory frameworks permit co-location at a single site provided cytotoxic operations are conducted in a physically separate, dedicated area with its own environmental controls, quality systems, and cleaning procedures. Shared infrastructure without this segregation creates cross-contamination risk that regulators will not accept.
Why is cytotoxic fill-finish CDMO capacity globally limited?
Establishing a compliant cytotoxic fill-finish capability requires significant capital investment, specialist engineering design, regulatory qualification, and a trained workforce. These barriers mean that even among established sterile injectable CDMOs, very few operate cytotoxic fill-finish at commercial scale under GMP conditions. Within Asia-Pacific in particular, the number of sites with full regulatory approval for cytotoxic injectable manufacturing is very small.
BioCina's Cytotoxic Manufacturing Capability
BioCina has operated a dedicated oncology fill-finish manufacturing for over 30 years. The oncology area encompasses purpose-built laboratories and RABS fill-finish lines, physically separated from the broader fill-finish platform. Fill volumes from 1 to 100 mL; batch sizes from 15 L to 1,180 L; 10M+ unit annual capacity. To discuss your oncology program, contact BioCina.
SME VERIFICATION REQUIRED | COUNTRY COUNT: The ’70+ countries’ figure for cytotoxic supply has not been flagged by SME for the cytotoxic questionnaire and is retained here. However, a separate SME note in the BFS questionnaire indicated that BFS-specific registered markets are now approximately 6. Confirm whether the 70+ countries claim is still valid for cytotoxic product supply specifically before publishing.
Reference
[1] Pharmaceutical Technology. Manufacturing Cytotoxics in a Multiproduct Facility. pharmaceutical-technology.com, October 2023.
[2] European Medicines Agency. Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities. EMA/CHMP/CVMP/SWP/169430/2012, February 2014.
[3] U.S. Food and Drug Administration. 21 CFR Parts 210 and 211: Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs.
[4] European Commission. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Part II and Annexes. EudraLex Volume 4.
Related pages: Cytotoxic Manufacturing | Sterile Vial Filling (RABS environment) | Discuss Your Oncology Program
Why Blow Fill Seal Technology Is Growing in Pharmaceutical Manufacturing
Blow fill seal technology is one of the fastest-growing segments in sterile pharmaceutical manufacturing.
Blow fill seal technology is one of the fastest-growing segments in sterile pharmaceutical manufacturing. A single continuous automated process forms, fills, and hermetically seals plastic containers, eliminating open-air exposure at the critical fill point. As demand for preservative-free formulations, single-dose sterile liquids, and high-volume aseptic packaging accelerates, blow fill seal (BFS) technology is attracting sustained investment from pharmaceutical manufacturers, generic drug companies, and hospital supply chains worldwide, with contract BFS manufacturing partnerships increasingly the model of choice for commercial-scale sterile liquid programs.
What Is Blow Fill Seal Technology?
BFS is an advanced aseptic manufacturing technology that forms, fills, and hermetically seals a plastic container in one continuous automated process. Unlike conventional vial or glass ampoule filling, where the container arrives pre-formed and is exposed to the surrounding environment during filling, BFS creates the container from pharmaceutical-grade low-density polyethylene (LDPE) at the point of fill.
Because the container never exists as an open vessel, BFS delivers a higher inherent sterility assurance than conventional filling. Practical benefits for pharmaceutical manufacturers and patients include:
- Shatterproof, tamper-proof containers with no glass breakage or particulate risk
- Preservative-free single-dose or multi-dose options
- Hermetically sealed with 100% inline leak testing
- Freezable container formats for cold chain programs
- High-volume output at lower per-unit cost than glass ampoule lines
Five Reasons BFS Demand Is Accelerating
1. Preservative-Free Formulation Trends
Regulatory agencies and clinicians increasingly require preservative-free formulations, particularly for ophthalmic, inhalation, and injectable medications. BFS enables preservative-free single-dose presentations at commercial scale, making it the natural manufacturing platform for this growing segment.
2. Growth in Ophthalmic and Respiratory Therapy Manufacturing
Ophthalmic drops and respiratory inhalation solutions are the largest application categories for BFS. Rising chronic respiratory disease burden, age-related eye disease, and expanded access programs in emerging markets are driving sustained volume growth for these product types globally.
3. Hospital Shift to Ready-to-Use Packaging
Hospitals and healthcare systems are transitioning to ready-to-use injectable and irrigation packaging to reduce preparation errors and minimize contamination risk in clinical settings. BFS-formatted products satisfy this requirement without requiring in-hospital compounding.
4. Tightening Regulatory Standards for Sterile Packaging
The 2022 revision of EU Annex 1 raised expectations for contamination control across sterile pharmaceutical manufacturing. BFS technology, with its inherently closed forming and filling process, aligns naturally with these evolving standards.
5. Sustained Single-Dose Adoption Post-COVID-19
The COVID-19 pandemic accelerated industry preference for single-dose formats across sterile liquid categories, reducing cross-contamination risk and simplifying administration. This structural shift has created lasting downstream demand for BFS manufacturing capacity.
Market Growth: Key Figures
Independent market research consistently identifies BFS technology as a high-growth segment within pharmaceutical packaging CDMO evaluating capacity investment. While valuations vary by scope, the directional consensus is consistent:
- The global BFS technology market was valued at approximately USD 3.2 to 3.8 billion in 2025 across major research organizations
- Projected compound annual growth rates range from 6% to 10% through 2032 to 2035, depending on the research scope
- Asia-Pacific is the fastest-growing region for new BFS installations, driven by pharmaceutical manufacturing expansion in China, India, and Southeast Asia
- Pharmaceuticals represent approximately 75% of the BFS market by application, led by ophthalmic and injectable sub-segments
- Over 12 billion BFS-packaged pharmaceuticals were produced globally in 2024, reflecting continued acceleration in single-dose sterile liquid output
BFS Applications in Pharmaceutical Manufacturing
Blow fill seal technology is deployed across a broad range of sterile liquid manufacturing categories. BioCina’s platform spans all four major segments across 40+ validated presentations:
| Application | Common Product Types |
|---|---|
| Ophthalmic | Eye drops, single-dose preservative-free preparations |
| Inhalation | Nebuliser solutions, respiratory inhalation liquids (1 to 2.5 mL) |
| Irrigation | Wound irrigation, surgical flush solutions (up to 30 mL) |
| Sterile injectables | Small-volume injectables, electrolyte solutions |
| Vaccine diluents | Reconstitution liquids, vaccine vehicle solutions |
| Headspace O2 | Less than 5% achievable |
What to Look for in a BFS Manufacturing Partner
Not all BFS CDMO partners offer equivalent capability. The technology is highly specialized and the right partner selection comes down to four practical considerations.
The first is capacity and scheduling reliability. High-volume blow fill seal manufacturing services require a partner with substantial annual unit output operating 24×7 shifts, with enough throughput reserve to absorb commercial-scale demand without compromising supply schedules.
The second is format breadth. A partner supporting ophthalmic, inhalation, irrigation, and injectable head-mold formats within a single qualified site reduces the client qualification burden and simplifies supply chain management across a sterile liquid portfolio.
The third is regulatory approval depth. Products targeting the US, Europe, and Asia-Pacific markets simultaneously require FDA, EMA, and TGA approval of the manufacturing site. Single-site multi-jurisdictional approval eliminates the complexity of managing multiple CMC packages and supply relationships.
The fourth is operational track record. BFS is a specialized technology, and decades of continuous operation build the institutional knowledge, process discipline, and regulatory inspection history that newer platforms cannot replicate. As an established aseptic fill-finish CDMO, BioCina has operated BFS manufacturing for over 30 years, with 200M+ unit annual capacity, 40+ validated presentations, and approvals including EMA and TGA, supported by integrated formulation development and analytical services.
FAQs
What is BFS packaging in pharmaceuticals?
BFS packaging is a type of aseptic primary packaging in which a plastic container, typically low-density polyethylene (LDPE), is blow-formed, filled, and hermetically sealed in one continuous automated process, significantly limiting open-air exposure at the critical fill point. In shuttle-type machines, HEPA-filtered Grade A air protects the fill zone during the brief fill cycle. This is the sterility assurance advantage of BFS over conventional glass vial or ampoule filling, where the container arrives pre-formed and is exposed to the surrounding environment during the fill step.
What products use blow fill seal technology?
BFS technology is most commonly used for ophthalmic solutions, respiratory inhalation liquids, surgical and wound irrigation fluids, sterile injectable diluents, and single-dose vaccine diluents. It is particularly suited to preservative-free formulations and high-volume hospital supply products.
Is BFS technology suitable for biologics?
BFS is primarily used for small molecule sterile liquids and has been most widely validated for ophthalmic, inhalation, and injectable diluent categories. Biologic drug products, due to their molecular complexity and sensitivity to process conditions, are more commonly filled via aseptic vial filling or isolator-based platforms. For specific biologic programs, feasibility assessment with a qualified development team is recommended.
How does BFS compare to glass ampoule filling?
BFS offers several practical advantages over traditional glass ampoule filling: the plastic LDPE container is shatterproof and eliminates glass particle contamination risk; the enclosed forming and filling process provides higher sterility assurance than open-vessel filling; single-dose presentations reduce dosing errors; and at commercial scale, BFS typically delivers higher throughput and lower per-unit cost than glass ampoule lines.
BioCina's BFS Manufacturing Platform
BioCina has led Blow-Fill-Seal manufacturing for over 30 years, with 200M+ unit annual capacity across 40+ presentations. Fill volumes from 1 to 30 mL; batch sizes from 105 L to 25,000 L. Multi-jurisdictional approvals include FDA, EMA, and TGA. To discuss your program, contact BioCina.
SME VERIFICATION REQUIRED | EU ANNEX 1 STATUS: SME confirmed that currently only 1 BFS line is Annex 1 compliant; a second line (BFS line 1) is expected to be compliant mid-2026. This claim has been intentionally excluded from the blog body to avoid overclaiming. Confirm the exact number of compliant lines at the point of publication and decide whether to include this detail in the CTA callout.
[1] Persistence Market Research. Blow Fill Seal Technology Market Size and Future Growth 2032. persistencemarketresearch.com, 2025.
[2] FactMR. Blow Fill Seal Technology Market Share and Statistics 2035. factmr.com, 2025.
[3] Market Growth Reports. Blow Fill Seal Technology Market Size. marketgrowthreports.com, 2024.
[4] European Commission. Annex 1 to EU Guidelines for Good Manufacturing Practice: Manufacture of Sterile Medicinal Products. EudraLex Volume 4, August 2022.
[5] Future Market Insights. Blow Fill Seal Technology Market: Global Market Analysis Report 2035. futuremarketinsights.com, April 2026.
Related pages: Blow-Fill-Seal Ampoules | Diluent Services | Discuss Your BFS Program
What Is an Isolator Filling Workcell?
An isolator filling workcell is a robotic, closed-system aseptic filling platform designed to eliminate human presence from the critical fill environment. Purpose-built for sterile fill-finish isolator operations, it achieves the highest level of sterility assurance available in GMP pharmaceutical manufacturing.
An isolator filling workcell is a robotic, closed-system aseptic filling platform designed to eliminate human presence from the critical fill environment. Purpose-built for sterile fill-finish isolator operations, it achieves the highest level of sterility assurance available in GMP pharmaceutical manufacturing. For drug developers evaluating fill-finish options, particularly for biologics, oxygen-sensitive molecules, and orphan drug programs, understanding this platform is essential to making the right manufacturing decision.
How an Isolator Filling Workcell Works
In conventional aseptic manufacturing, personnel working within cleanrooms or behind restricted access barrier systems (RABS) represent the primary source of microbial and particulate contamination.
An isolator filling workcell addresses this by operating as a fully closed system with no direct human access to the filling zone. BioCina’s SA25 Cytiva robotic aseptic isolator illustrates the design: ready-to-use (RTU) components are loaded through a biodecontamination staging chamber, where a validated sanitization cycle achieves a minimum 6-log reduction in bioburden before transfer. Filling and closure then occur in a downstream sealed filling isolator with all material handling performed robotically.
Internal air throughout the critical zone is maintained at ISO Class 5 / Grade A quality through HEPA filtration and controlled unidirectional airflow. With no glove ports and no conveyor belts passing through the fill environment, isolator fill finish eliminates the principal contamination variables present in conventional cleanroom and RABS operations entirely.
Isolator vs RABS vs Traditional Aseptic Filling
| Environment | Human Separation | Best Suited For |
|---|---|---|
| Traditional cleanroom | Personnel gowned and present throughout | Lower-risk formulations, high-volume commodity products |
| RABS | Rigid barrier; interventions via glove ports | High-potency and cytotoxic injectables; cost-effective aseptic isolator filling |
| Isolator filling workcell | Fully closed; robotic handling; no glove ports | Biologics, oxygen-sensitive molecules, orphan drugs, programs where maximum contamination control assurance is required |
Three environments are used for aseptic fill-finish. Each offers a different level of operator separation and sterility assurance:
What Products Are Best Suited for Isolator Filling
The isolator’s combination of sterility assurance, format flexibility, and containment makes it the platform of choice for:
- Biologic drug products, including monoclonal antibodies, recombinant proteins, peptides, and antibody fragments
- Oxygen-sensitive formulations requiring headspace O2 control below 5% and nitrogen blanketing
- Orphan and rare disease programs with small commercial batch sizes requiring full GMP compliance
- Clinical trial supply from Phase I through Phase III at flexible batch sizes
- mRNA, cell and gene therapy products requiring the highest achievable aseptic conditions
- Biosimilar fill-finish programs targeting FDA, EMA, or TGA regulatory submissions
Key Technical Parameters: SA25 Cytiva Platform
The SA25 Cytiva robotic aseptic isolator is one of the pharmaceutical industry’s leading isolator filling workcell platforms. Representative specifications:
| Parameter | Detail |
|---|---|
| Fill volume range | 0.5 mL to 50 mL |
| Batch size range | 0.5 L to 500 L (approx. 100 to 20,000 units) |
| Vial formats | 2 mL, 6 mL, 10 mL |
| Syringe formats | 1 mL, 5 mL (glass and plastic; luer-lock and staked needle) |
| Cartridge formats | 3 mL |
| Headspace O2 | Less than 5% achievable |
| Viscosity handling | 1 cP to 40 cP |
| Key features | Nitrogen overlay, vacuum stoppering, fully robotic material handling |
| Compliance | EU Annex 1 compliant |
| Annual capacity (BioCina) | 5M+ units |
EU Annex 1 Compliant Aseptic Filling
The 2022 revision of EU Annex 1, the European GMP guideline governing sterile medicinal product manufacture, elevated the standard for aseptic processing globally. The revised guideline requires manufacturers to implement a documented contamination control strategy (CCS) and places strong emphasis on barrier technologies, including isolators, as the preferred approach for high-risk aseptic operations.
An isolator filling workcell, with its Grade A filling environment, validated biodecontamination cycle, and fully robotic material handling, directly satisfies the contamination control requirements the 2022 revision specifies. BioCina’s SA25 isolator filling workcell is EU Annex 1 compliant, operating within a GMP sterile manufacturing environment designed for global regulatory readiness. The facility’s contamination control strategy (CCS) is documented and validated to the standards EMA regulatory inspections, making it an audit-ready option for programs targeting European market authorisation or applying EU GMP standards as a global quality baseline.
FAQs
What is the difference between an isolator and RABS?
Both restrict access to the filling zone, but they differ in the degree of separation. A RABS uses a rigid barrier with gloved interventions. An isolator is fully closed with no glove ports and no human presence in the fill environment during operation. Isolators provide higher sterility assurance because the primary contamination source, the operator, is excluded from the critical zone entirely.
What products can be filled in an isolator filling workcell?
Isolator filling workcells support biologics, oxygen-sensitive formulations, mRNA and cell therapy products, orphan drugs, and clinical trial supply programs where the highest sterility assurance is required. They accommodate vials, pre-filled syringes, and cartridges within a single qualified platform.
How does an isolator filling workcell achieve EU Annex 1 compliance?
Compliance is achieved through closed system design, HEPA-filtered Grade A air, validated biodecontamination cycles, and fully robotic material handling. These features collectively address the contamination control strategy requirements in the 2022 Annex 1 revision, which explicitly identifies isolators as the preferred solution for high-risk aseptic filling.
Is an isolator filling workcell suitable for clinical-stage programs?
Yes. Batch size flexibility, ranging from sub-liter clinical runs to several hundred liters, makes isolator filling workcells well suited to Phase I through pivotal Phase III supply. The platform is particularly relevant for orphan drug programs where small commercial batches must meet the same GMP standards as large-volume commercial manufacturing.
BioCina's Isolator Filling Workcell
BioCina operates the SA25 Cytiva robotic aseptic isolator at its sterile drug product facility. EU Annex 1 compliant. Supports glass vials (2, 6, 10 mL), pre-filled syringes (1, 5 mL in glass and plastic), and cartridges (3 mL). Fill volumes from 0.5 to 50 mL. 5M+ unit annual capacity. To discuss your program, contact BioCina’s technical team.
[1] Cytiva. SA25 Aseptic Filling WorkCell: Product Overview. cytivalifesciences.com, 2024.
[2] Syntegon. Pharmaceutical Isolator and Barrier Systems: Integrated Air Management and Filling Solutions. syntegon.com, 2024.
[3] European Commission. Annex 1 to EU Guidelines for Good Manufacturing Practice: Manufacture of Sterile Medicinal Products. EudraLex Volume 4, August 2022.
[4] Körber Pharma. Aseptic Isolator: Pharmaceutical Glossary. koerber-pharma.com, 2024.
[5] Pharmaceutical Technology. The Advantages of Isolator Lines for Large-Scale Pharma Manufacturing. pharmaceutical-technology.com, May 2025.